What Happened
Amgen has moved MariTide, its investigational obesity therapy, into a broad Phase 3 program called MARITIME that spans six global studies. The scope of the program signals the company's intent to test the compound across a range of conditions linked to obesity, not just weight management alone. Launching six studies at once is a substantial undertaking and reflects a strategy of evaluating MariTide as a platform rather than a single-indication drug.
What MariTide Is
MariTide, known generically as maridebart cafraglutide and formerly as AMG 133, is a peptide-antibody conjugate. It combines a GIP-receptor antagonist with a GLP-1 receptor agonist. That antagonist-plus-agonist design is distinctive: rather than activating both incretin receptors, it blocks GIP while stimulating GLP-1. That is a mechanistic bet that differs from the dual-agonist approach of tirzepatide, which activates both GIP and GLP-1. The contrast between antagonizing and agonizing GIP is one of the more debated questions in incretin science, and MariTide is a large-scale test of the antagonist side of that debate.
The conjugate structure also supports a once-monthly dosing schedule, a notable departure from the weekly cadence common across the injectable GLP-1 field. Less frequent dosing is one of the central features Amgen is positioning around, on the reasoning that a monthly injection could ease the burden of ongoing treatment.
The Phase 2 Signal
A phase 2 study showed up to about 20% weight loss. That result, from a mid-stage trial, is what underpinned the decision to launch a large Phase 3 effort. As with all earlier-stage data, it describes a defined study population and does not predict what the registrational trials will demonstrate. Carrying a roughly 20% signal into a six-study program indicates Amgen judged the effect durable enough to justify broad late-stage testing.
The Six-Study Program
The MARITIME program is unusually broad. It includes MARITIME-1 and MARITIME-2, focused on chronic weight management with and without type 2 diabetes; MARITIME-CV, a cardiovascular outcomes study; MARITIME-HF, focused on heart failure; and MARITIME-OSA-1 and MARITIME-OSA-2, addressing obstructive sleep apnea. A type 2 diabetes phase 3 was planned to begin in 2026 as well. That spread reflects a strategy of testing MariTide against the constellation of conditions that cluster with obesity, from cardiovascular and heart-failure risk to sleep-disordered breathing, mirroring the multi-indication paths other GLP-1-based agents have taken.
MariTide is not FDA-approved. It remains an investigational compound, and every element of the MARITIME program is part of the evidence-gathering process rather than a settled result. That status is central to how the program should be understood: it is a set of hypotheses being tested at scale, not a menu of established uses.
What It Means
The breadth of the MARITIME program illustrates how obesity therapeutics are increasingly being studied as platforms addressing multiple linked conditions. The once-monthly dosing and the GIP-antagonist mechanism give MariTide a differentiated profile within an increasingly crowded field. Its results will help clarify both whether monthly dosing holds up and whether antagonizing GIP, rather than activating it, delivers the advantages Amgen is betting on.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.